Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Dr., MS 5023, Indianapolis, IN, 46202, USA.
Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.
Curr Osteoporos Rep. 2019 Feb;17(1):16-25. doi: 10.1007/s11914-019-00499-w.
The receptor for advanced glycation end products (RAGE) and several of its ligands have been implicated in the onset and progression of pathologies associated with aging, chronic inflammation, and cellular stress. In particular, the role of RAGE and its ligands in bone tissue during both physiological and pathological conditions has been investigated. However, the extent to which RAGE signaling regulates bone homeostasis and disease onset remains unclear. Further, RAGE effects in the different bone cells and whether these effects are cell-type specific is unknown. The objective of the current review is to describe the literature over RAGE signaling in skeletal biology as well as discuss the clinical potential of RAGE as a diagnostic and/or therapeutic target in bone disease.
The role of RAGE and its ligands during skeletal homeostasis, tissue repair, and disease onset/progression is beginning to be uncovered. For example, detrimental effects of the RAGE ligands, advanced glycation end products (AGEs), have been identified for osteoblast viability/activity, while others have observed that low level AGE exposure stimulates osteoblast autophagy, which subsequently promotes viability and function. Similar findings have been reported with HMGB1, another RAGE ligand, in which high levels of the ligand are associated with osteoblast/osteocyte apoptosis, whereas low level/short-term administration stimulates osteoblast differentiation/bone formation and promotes fracture healing. Additionally, elevated levels of several RAGE ligands (AGEs, HMGB1, S100 proteins) induce osteoblast/osteocyte apoptosis and stimulate cytokine production, which is associated with increased osteoclast differentiation/activity. Conversely, direct RAGE-ligand exposure in osteoclasts may have inhibitory effects. These observations support a conclusion that elevated bone resorption observed in conditions of high circulating ligands and RAGE expression are due to actions on osteoblasts/osteocytes rather than direct actions on osteoclasts, although additional work is required to substantiate the observations. Recent studies have demonstrated that RAGE and its ligands play an important physiological role in the regulation of skeletal development, homeostasis, and repair/regeneration. Conversely, elevated levels of RAGE and its ligands are clearly related with various diseases associated with increased bone loss and fragility. However, despite the recent advancements in the field, many questions regarding RAGE and its ligands in skeletal biology remain unanswered.
晚期糖基化终产物(RAGE)受体及其配体已被牵涉到与衰老、慢性炎症和细胞应激相关的病理的发生和进展中。特别是,RAGE 及其配体在生理和病理条件下的骨组织中的作用已经被研究过了。然而,RAGE 信号调节骨稳态和疾病发生的程度尚不清楚。此外,RAGE 在不同的骨细胞中的作用及其是否具有细胞类型特异性也尚不清楚。本综述的目的是描述 RAGE 信号在骨骼生物学中的文献,并讨论 RAGE 作为骨疾病的诊断和/或治疗靶点的临床潜力。
RAGE 及其配体在骨骼稳态、组织修复和疾病发生/进展中的作用开始被揭示。例如,已经发现 RAGE 配体(晚期糖基化终产物[AGE])对成骨细胞活力/活性具有有害影响,而另一些研究则观察到低水平 AGE 暴露刺激成骨细胞自噬,进而促进细胞活力和功能。另一种 RAGE 配体高迁移率族蛋白 B1(HMGB1)也有类似的发现,其中配体的高水平与成骨细胞/破骨细胞凋亡有关,而低水平/短期给药刺激成骨细胞分化/骨形成并促进骨折愈合。此外,几种 RAGE 配体(AGEs、HMGB1、S100 蛋白)水平升高会诱导成骨细胞/破骨细胞凋亡并刺激细胞因子产生,这与破骨细胞分化/活性增加有关。相反,直接在破骨细胞中暴露于 RAGE 配体可能具有抑制作用。这些观察结果支持这样的结论,即在高循环配体和 RAGE 表达的情况下观察到的骨吸收增加是由于对成骨细胞/破骨细胞的作用,而不是对破骨细胞的直接作用,尽管需要进一步的研究来证实这些观察结果。最近的研究表明,RAGE 及其配体在骨骼发育、稳态和修复/再生的调节中发挥着重要的生理作用。相反,RAGE 及其配体水平的升高显然与各种与骨丢失和脆弱性增加相关的疾病有关。然而,尽管该领域最近取得了进展,但 RAGE 及其配体在骨骼生物学中的许多问题仍未得到解答。